Free Newsletter
FDA gets meager funding boost
Any big fix at the FDA may have to wait for a new president. The White House's proposed budget includes a funding increase of just 5.7 percent for the agency, a hike that's significantly absorbed by inflation. It's a far cry from the double-or-nothing some experts have said is crucial to bringing the FDA up to speed.
The $2.4 billion budget won't be greeted by cheers from any but the most die-hard anti-government types. Over the past couple of months, report after report has shown that FDA is in dire need of more bucks and more bodies to deal with big leaps forward in science and huge increases in imports of food and drugs.
Of course Congress might boost FDA funding levels, but that boost would have to make it past the president's desk. For his part, Commissioner Andrew von Eschenbach sounded sanguine about the proposal--"This budget enables us to continue development of the staff and programs necessary," he said in a statement--but it is his boss's budget, after all. Other observers weren't so satisfied. Without Congressional intervention, the agency will be stuck "treading water," one expert said.
- see the FDA's release
- read the report from USA Today
- check out the article in the Wall Street Journal
Related Articles:
FDA in crisis? Then show them the money. Report
Agreed in committee: FDA needs money. Report
GAO assails FDA's foreign inspections. Report
FDA wants satellite offices overseas. Report
FDA badly needs more money, staff. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: